Lexeo TherapeuticsLXEO
Recorded

Lexeo Therapeutics 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration53 minParticipants13

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good morning, and welcome to the Lexeo Therapeutics webcast presentation. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. As a reminder, this call is being recorded. I would like now to turn the conference over to Louis Tamayo, Chief Financial Officer at Lexeo Therapeutics. Louis, please go ahead. Thank you.

Louis TamayoCFO

Earlier today, we released interim data from the Lexeo HEROIC-PKP2 phase I/II clinical trial of LX2020 for the treatment of PKP2-associated arrhythmogenic cardiomyopathy, or ACM. The press release outlining the interim data update is available on our website, as are the slides related to today's call. Before we begin, I would like to remind everyone that today's discussion contains forward-looking statements regarding Lexeo's future expectations, plans, and prospects, which constitute forward-looking statements for the purposes of the Safe Harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our filings with the SEC. With that, I will turn the call over to our CEO, Nolan.

R. Nolan TownsendCEO

Thanks, Lou. We are pleased to share positive clinical data today demonstrating exciting, clinically meaningful improvements for patients with PKP2 ACM. In the high-dose cohorts, we observed an 80% mean reduction in NSVT burden and a 44% mean reduction in PVC burden at latest assessment. We also observed favorable patient-reported outcomes, encouraging trends in cardiac function, supportive biopsy data, and a well-tolerated safety profile, further strengthening the overall body of evidence for LX2020. We look forward to reviewing these data in greater detail this morning. Importantly, we have also received FDA feedback indicating that the agency is open to guideline-defined NSVT as a surrogate endpoint in a pivotal study for accelerated approval of LX2020. We intend to evaluate NSVT through a responder-based analysis using an established, clinically validated risk threshold, which we will discuss later today.

R. Nolan TownsendCEO

We currently estimate the pivotal sample size for accelerated approval would include roughly 60 to 80 patients across both treatment and control arms. Given that arrhythmia burden is a key feature of PKP2 ACM, we also expect to incorporate additional measures into the pivotal study, including PVC burden and ICD events, to further characterize clinical benefit. We will continue regulatory discussions with the FDA early next year to finalize the pivotal study design, statistical analysis plan, and confirmatory evidence strategy. Overall, these clinical and regulatory updates strengthen our confidence in the potential of LX2020 to become the first disease-modifying therapy for PKP2 ACM, and we intend to initiate a pivotal study under the accelerated approval pathway in the second half of 2027. Alongside the potential for clinical impact in a patient population with significant unmet need, we believe PKP2 ACM represents a highly attractive commercial opportunity.

R. Nolan TownsendCEO

Based on the addressable population and the potential value proposition of a one-time disease-modifying therapy, we are confident that LX2020 has the potential to support a multi-billion dollar market opportunity. Importantly, patients are concentrated at a relatively small number of specialized heart failure centers globally, enabling efficient reach, rapid trial enrollment, and a streamlined path to commercial adoption. We also believe Lexeo is well-positioned from a manufacturing perspective, with a scalable production platform designed to support the anticipated commercial demand of a population of this size. Ultimately, commercial success will be driven by our ability to deliver meaningful benefit for patients. The encouraging efficacy and safety data we shared today further strengthen our belief that LX2020 has the potential to become the first disease-modifying therapy for PKP2 ACM, and if successful, addresses a significant unmet need for patients while creating substantial value for shareholders.

R. Nolan TownsendCEO

With that, I will turn the call over to Nani Bhalla, our Chief Medical Officer, to review the clinical data in greater detail.

Nani BhallaChief Medical Officer

Thank you, Nolan. Before we review the data, it is important to understand how we assess treatment response in PKP2 ACM. We evaluate efficacy across three complementary domains: arrhythmic activity, including PVC and NSVT burden; myocardial structure and function, including right ventricular ejection fraction and free wall strain; and patient burden, including patient-reported outcomes. Together, these measures help us assess both clinical benefit and the potential for disease modification. As discussed previously and consistent with KOL feedback, ventricular arrhythmias in ACM exist along a spectrum of increasing clinical risk. PVCs are common and represent early manifestations of electrical instability. NSVT is defined by clinical guidelines as three or more consecutive ventricular beats lasting less than 30 seconds at a rate over 100 beats per minute, which is hemodynamically stable.

Nani BhallaChief Medical Officer

Guideline-defined NSVT carries greater prognostic significance than PVCs alone and is associated with a significantly higher risk of future sustained arrhythmias and sudden cardiac death. At the highest risk end of the spectrum are sustained ventricular tachycardia, ICD shocks, and other serious clinical outcomes. NSVT is one of the strongest predictors of future sustained life-threatening ventricular arrhythmias in ACM. That is why it matters as a measure of disease activity and why it has emerged for us as a potential primary endpoint. A common question is how frequently NSVT occurs in patients with PKP2 ACM. As shown on this slide, NSVT is a well-established risk factor used in clinical decisions around ICD implantation, and about 75% of ACM patients receive an ICD during the course of their disease, whether for primary or secondary prevention.

Nani BhallaChief Medical Officer

Importantly, because both HEROIC and the SNAPSHOT Natural History Study enrolled patients with ICDs and a minimum daily threshold of PVCs, these studies selected for a population with substantial underlying arrhythmic risk, including high NSVT incidence. Consistent with that, between 80% and 100% of participants had documented NSVT on baseline Holter monitoring. In addition to arrhythmia burden, we also evaluate systolic function using cardiac MRI. In people with earlier stages of disease, ejection fraction may be stable. RV free wall strain, however, can be a more sensitive marker of muscle function that deteriorates earlier in ACM. Depending on the measurement technique and disease, abnormal wall strain values may be minus 10% to minus 18%-20% approximately, whereas normal wall strain values would be minus 20% to minus 25% to minus 30%. Abnormal wall strain is associated with increased risk in ACM of structural progression and future ventricular arrhythmias.

Nani BhallaChief Medical Officer

As we will discuss later, rescuing strain may represent improved right ventricular function, particularly if ejection fraction remains largely stable. To briefly cover the study design, HEROIC-PKP2 is a 52-week open-label study with four years of long-term follow-up. The study is fully enrolled with three participants treated at the low dose of 2e13 and seven at the high dose of 6e13 vector genomes per kilogram. As I just mentioned, all participants were required to have an ICD prior to entering the study and to meet a certain level of minimum PVCs, which inherently enriched the study population for those with more severe disease, including NSVT burden at baseline. We feel these inclusion criteria allowed us to enroll participants more likely to need and benefit from gene therapy treatment due to disease burden, and we expect to retain most of these criteria looking ahead in the planned pivotal study.

Nani BhallaChief Medical Officer

Baseline characteristics in HEROIC-PKP2 are consistent with the broader PKP2 ACM patient population, with more severe arrhythmia burden in the high-dose cohorts, specifically higher mean PVC and NSVT burden. Nine of 10 participants had a history of sustained VT. As of the October 15th data cutoff, follow-up ranges from nine to 24 months. At the high dose, six of the seven participants have reached at least one year of follow-up. As a reminder, in January of 2026, we evaluated and presented NSVT as total ventricular runs. At the time, that approach allowed us to capture the full spectrum of consecutive ventricular activity.

Nani BhallaChief Medical Officer

As we have progressed discussions with regulators and working towards establishing an endpoint with the highest clinical relevance in ACM for the purposes of a pivotal study, we are now focused on NSVT as defined in clinical guidelines, at least three consecutive ventricular beats at a rate greater than 100 beats per minute, terminating spontaneously within 30 seconds. The FDA has also agreed with this definition. As a result, the baseline data were updated using this framework. NSVT event counts decreased because ventricular runs occurring at rates below 100 beats per minute were reclassified as PVCs. Remember, the guideline definition of NSVT notes runs above 100 beats per minute. Importantly, this does not change the underlying ECG recordings or the ventricular activity that occurred. It provides a more clinically meaningful way to classify that activity and evaluate change over time.

Nani BhallaChief Medical Officer

Turning now to the clinical data, we have seen encouraging signals of response across arrhythmia burden, cardiac function, and patient-reported outcomes. Patients with a clinically relevant positive response are highlighted in green on the slide. at the latest visit, mean NSVT in the high-dose cohorts improved 80%, and mean PVCs improved 44%. NSVT declined in six of seven participants treated with high dose, with reductions of 75% or more in five participants, well exceeding the impact of current interventions and standard of care. PVCs declined in five of seven participants, and five of seven reported symptom improvement on the Patient Global Impression of Change scale. Five of seven participants also showed improvement in RV free wall strain, with four approaching the lower limit of normal, around -18% to -20%.

Nani BhallaChief Medical Officer

Ejection fraction was stable in the majority of participants, although we do see one participant with significant improvement in RVEF at the latest assessment at 18 months. Looking across all parameters together, you can see that every participant in the high-dose cohort showed improvement in at least two parameters of interest, and most showed improvements in three parameters. Overall, these results demonstrated compelling and consistent treatment effect and give us great confidence in the potential of LX2020. Looking at NSVT improvement over time, you can see that mean NSVT reductions in the high-dose cohort continue to deepen with longer follow-up, with mean NSVT falling from approximately 13 episodes per week at baseline to approximately six episodes per week at 12 months and five episodes per week at 18 months. In contrast, participants in the Lexeo-sponsored SNAPSHOT Natural History Study experienced a 53% mean increase in NSVT over 12 months.

Nani BhallaChief Medical Officer

We observed a dose-response treatment effect both in comparison to natural history and the treated patient cohorts at baseline. In the literature and in current clinical practice, NSVT is often assessed in a binary manner. The absence of NSVT reduces future arrhythmic risk, and the presence of NSVT increases risk. Hence, less than one NSVT episode per day is a clinically relevant threshold for management and risk monitoring in ACM. The threshold often used to define the presence of NSVT is more than one episode per day or more than seven episodes per week, and patients above this threshold have a greater risk of future sustained VT events, sometimes irrespective of PVC burden. Importantly, the strength of NSVT as a potential surrogate accelerated approval endpoint lies in its ability to define improvement prospectively against this clinically established threshold, providing a clear and meaningful benchmark for treatment effect.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day